Evaluation of the cloned enzyme donor immunoassay for measurement of phenytoin and phenobarbital in serum

Evaluation of fluorescence polarization assays for measuring valproic acid, phenytoin, carbamazepine and phenobarbital in serum

The authors evaluated the fluorescence polarization (FP) assay on the COBAS INTEGRA 700 using COBAS INTEGRA reagent system cassettes for estimating the antiepileptic drugs valproic acid, phenytoin, carbamazepine, and phenobarbital in serum. The study comprised the determination of precision, method comparison performed against a conventional HPLC assay and linearity studies, according to the National Committee for Clinical Laboratory Standards (NCCLS) protocols. Precision results were well acceptable for all FP assays. Intra-assay coefficients of variation (CVs) were from 1.3% to 2.4% for valproic acid, from 0.8% to 2.8% for phenytoin, from 1.7% to 3.3% for carbamazepine, and from 1.3% to 2.3% for phenobarbital. Interassay CVs for these drugs ranged from 1.5% to 2.6%, from 2.9% to 6.5%, from 1.8% to 3.7% and from 1.5% to 3.2%, respectively. Results of the FP assays showed excellent correlation with those from HPLC: r = 0.99 for valproic acid, r = 0.98 for phenytoin, r = 0.98 for carbamazepine and r = 0.99 for phenobarbital. Linearity was satisfactory, with all CVs below the acceptable level. With the COBAS INTEGRA 700 analyzer FP assays are fully automated, which is less laborious and saves time compared with HPLC. Moreover, the fast measuring procedure is convenient in short turnaround time (STAT) analysis. It is an analytically reliable and rapid system, which can be used successfully for the therapeutic monitoring of antiepileptic drugs in serum.

The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement

The cytochrome P450 enzyme CYP2C9 catalyses the metabolism of numerous therapeutic agents, including the anti-epileptic drug phenytoin. CYP2C9 is genetically polymorphic: two allelic variants are known, CYP2C9*2 and CYP2C9*3, differing from the wild-type CYP2C9*1 by a single point mutation. Both mutant alleles are associated with markedly impaired metabolic capacity for many CYP2C9 substrates compared to the wild-type, resulting in raised serum drug levels upon a given dose. Because this may be relevant in treatment with phenytoin, we studied the effect of CYP2C9 genotype on phenytoin dose requirement in a group of 60 epileptic patients on long-term phenytoin therapy. CYP2C9 genotyping was performed by polymerase chain reaction analysis, phenytoin serum concentrations were measured by high-performance liquid chromatography analysis and related to the maintenance doses. For patients carrying at least one mutant CYP2C9 allele (n = 17), the mean phenytoin dose required to achieve a therapeutic serum concentration was about 37% lower than the mean dose required by wild-type individuals (199 mg/day versus 314 mg/day; P < 0.01). A low maintenance dose (< 200 mg/day) sufficed for 47% of carriers, while 58% of normals required a high dose (> 300 mg/day) for an effective serum level. The results show that there is a strong association between CYP2C9 allelic variants and phenytoin dose requirement. Since phenytoin has a narrow therapeutic index and genotyping may be carried out rapidly and at low cost, dosage adjustment based on CYP2C9 genotype, especially at the induction of therapy, would be of value in order to lower the risk of concentration dependent drug intoxications in carriers.